Sutro Biopharma 관리
관리 기준 확인 2/4
Sutro Biopharma CEO는 Bill Newell, Jan2009 에 임명되었습니다 의 임기는 15.83 년입니다. 총 연간 보상은 $ 2.13M, 32.2% 로 구성됩니다. 32.2% 급여 및 67.8% 보너스(회사 주식 및 옵션 포함). 는 $ 845.19K 가치에 해당하는 회사 주식의 0.41% 직접 소유합니다. 845.19K. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 5.4 년입니다.
주요 정보
Bill Newell
최고 경영자
US$2.1m
총 보상
| CEO 급여 비율 | 32.2% |
| CEO 임기 | 15.8yrs |
| CEO 소유권 | 0.4% |
| 경영진 평균 재임 기간 | 1.8yrs |
| 이사회 평균 재임 기간 | 5.4yrs |
최근 관리 업데이트
Recent updates
Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive
Oct 11
Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology
Sep 23There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise
Aug 24Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts
Aug 22Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results
Aug 16The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%
Jun 26We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right
May 31Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates
Apr 02The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet
Mar 28Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Dec 19Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Aug 24Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
Feb 10An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued
Jan 12Sutro Biopharma: Partnership Progress Warrants Exposure
Aug 16New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)
Aug 11Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M
Aug 08Sutro to get $10M payment from Merck after first patient dosed in collaboration trial
Jul 26Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
May 02Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching
Dec 27Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?
Dec 26Sutro Biopharma initiated buy at H.C. Wainwright citing ADC candidates
Jun 18Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts
May 09CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$124m |
| Jun 30 2024 | n/a | n/a | -US$124m |
| Mar 31 2024 | n/a | n/a | -US$115m |
| Dec 31 2023 | US$2m | US$687k | -US$107m |
| Sep 30 2023 | n/a | n/a | -US$172m |
| Jun 30 2023 | n/a | n/a | -US$143m |
| Mar 31 2023 | n/a | n/a | -US$130m |
| Dec 31 2022 | US$3m | US$663k | -US$119m |
| Sep 30 2022 | n/a | n/a | -US$123m |
| Jun 30 2022 | n/a | n/a | -US$134m |
| Mar 31 2022 | n/a | n/a | -US$114m |
| Dec 31 2021 | US$6m | US$625k | -US$106m |
| Sep 30 2021 | n/a | n/a | -US$127m |
| Jun 30 2021 | n/a | n/a | -US$79m |
| Mar 31 2021 | n/a | n/a | -US$43m |
| Dec 31 2020 | US$2m | US$554k | -US$32m |
| Sep 30 2020 | n/a | n/a | US$13m |
| Jun 30 2020 | n/a | n/a | -US$17m |
| Mar 31 2020 | n/a | n/a | -US$61m |
| Dec 31 2019 | US$4m | US$497k | -US$56m |
| Sep 30 2019 | n/a | n/a | -US$42m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$38m |
| Dec 31 2018 | US$9m | US$482k | -US$35m |
| Sep 30 2018 | n/a | n/a | -US$49m |
| Jun 30 2018 | n/a | n/a | -US$40m |
| Mar 31 2018 | n/a | n/a | -US$30m |
| Dec 31 2017 | US$703k | US$468k | -US$20m |
보상 대 시장: Bill 의 총 보상 ($USD 2.13M )은 US 시장( $USD 1.48M ).
보상과 수익: Bill 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Bill Newell (66 yo)
15.8yrs
테뉴어
US$2,129,980
보상
Mr. William J. Newell, also known as Bill, J.D. has been the Chief Executive Officer and Director of Sutro Biopharma, Inc. since February 2009. He served as Independent Director at Vaxcyte, Inc. since Nove...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Director | 15.8yrs | US$2.13m | 0.41% $ 845.2k | |
| Chief Scientific Officer | 1.2yrs | US$1.63m | 0.029% $ 60.5k | |
| Chief Medical Officer | 1.8yrs | US$2.34m | 0.030% $ 61.2k | |
| President & COO | less than a year | US$1.43m | 0.066% $ 136.2k | |
| Founder | no data | 데이터 없음 | 데이터 없음 | |
| CFO & Secretary | 11.8yrs | US$2.08m | 0.13% $ 267.9k | |
| Chief Technical Operations Officer | 1.5yrs | 데이터 없음 | 0.038% $ 79.6k | |
| General Counsel | 3.7yrs | 데이터 없음 | 데이터 없음 | |
| Chief People & Communications Officer | 16.8yrs | US$1.30m | 0.10% $ 209.2k | |
| Chief Business Development Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Vice President & Controller | no data | 데이터 없음 | 데이터 없음 |
1.8yrs
평균 재임 기간
62yo
평균 연령
경험이 풍부한 관리: STRO 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Director | 15.8yrs | US$2.13m | 0.41% $ 845.2k | |
| Independent Chair of the Board | 5.4yrs | US$173.11k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$138.11k | 0% $ 0 | |
| Independent Director | 10.8yrs | US$138.11k | 0.068% $ 141.4k | |
| Independent Director | 15.3yrs | US$140.11k | 0.027% $ 56.4k | |
| Member of Scientific Advisory Board | 1.8yrs | US$1.53m | 0.12% $ 251.9k | |
| Chair of the Scientific Advisory Board | 4.5yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 6.3yrs | US$133.11k | 0% $ 0 | |
| Independent Director | 7.8yrs | US$152.11k | 0% $ 0 | |
| Co-Chair of Clinical Advisory Board & Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of the Clinical Advisory Board | 4.5yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 3yrs | US$150.28k | 0% $ 0 |
5.4yrs
평균 재임 기간
66yo
평균 연령
경험이 풍부한 이사회: STRO 의 이사회는 경험(평균 재직 기간 5.4 년)으로 간주됩니다.